Author of

• 11946

  +

  P2.24 - Poster Session 2 - Supportive Care (ID 157)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12005

    +

    P2.24-059 - Results of treating advanced stage non small cell lung cancer by erlotinib at the Pulmonary Department, Cho Ray hospital: first vietnamese case report (ID 3445)

    09:30 - 09:30  |  Author(s): T.V. Ngoc
    • Abstract

    Background
    Lung cancer is the second cause of cancer death in Vietnam. Most of patients with lung cancer are non small cell (90%) and present at advanced stage. Erlotinib was the first EGFR TKI permitted to be used for advanced stage non small cell lung cancer in Vietnam since 2007. Safety and efficacy of this treatment has never been reported in Vietnamese patients. We present the first case report of erlotinib in Vietnamese advanced-stage non small cell lung cancer patients to study the safety and the efficacy of this treatment.

    Methods
    From 12/2007 to 12/2011 advanced stage (wet IIIB and IV) non small cell lung cancer patients diagnosed at Cho Ray hospital were prescribed erlotinib as (1) second/third line treatment or as (2) first line treatment only if they could not use standard, state of the art chemotherapy after well informed about different treatment options.

    Results
    High overall response 35.5%, median progression free survival of 7 months, median overall survival of 11 months and 1 year survival rate 50% were seen in 31 patients using erlotinib. These results were similar to East Asia patients but better than ones of Caucasian patients. Common adverse events were rash and diarrhea, severe adverse events were rare.

    Conclusion
    Erlotinib had high efficacy and low toxicity in Vietnamese patients like East Asian patients.